Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

31/07/2015
Spilling the beans

Failure to publish the results of all clinical trials is skewing medical science “I’M THE one who looks the patient in the eye and tells them the trial is beneficial,” says Tim Crater, a research physician at the Hutchinson Clinic in Kansas. Dr Crater runs drug tests for large pharmaceutical firms. He says volunteers are interested in more than just the promise of...

Read more...

Source Source: The Economist





31/07/2015
White House releases updated National HIV/AIDS Strategy

On July 30 the White House released an updated version of its National HIV/AIDS Strategy, outlining the administration's plans through the year 2020. In keeping with recent research, the revised strategy includes an increased emphasis on early antiretroviral treatment and pre-exposure prophylaxis (PrEP), as well as focusing on underserved and heavily affected population groups including...

Read more...





31/07/2015
Waking up HIV: Two compounds show great potential to rouse latent virus

Highly active anti-retroviral therapy (HAART) has helped millions survive the human immunodeficiency virus (HIV). Unfortunately, HIV has a built-in survival mechanism, creating reservoirs of latent, inactive virus that are invisible to both HAART and the immune system. But now, researchers at UC Davis have identified a compound that activates latent HIV, offering the tantalizing...

Read more...

Source Source: UC Davis





31/07/2015
HVTN 505 vaccine induced antibodies nonspecific for HIV

NIH-supported study explores why candidate HIV vaccine was not protective ​WHAT: A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine...

Read more...





31/07/2015
Four reasons IAS 2015 will be a milestone HIV conference: a personal view

The IAS 2015 held in Vancouver from 20-23 July was an exciting meeting. It should be seen as a milestone conference that will change the way adult HIV is treated globally. Results from antiretroviral treatment (ART), prevention and programmatic studies naturally dovetailed to provide a new evidence base for rethinking historical approaches to HIV management in order to...

Read more...

Source Source: HIV i-Base